Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study

New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment

(2017) Yameng Sun et al.   HEPATOLOGY

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

(2017) Pietro Lampertico et al.   JOURNAL OF HEPATOLOGY

Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach

(2017) P. H. Naylor et al.   JOURNAL OF VIRAL HEPATITIS

Liver Fibrosis Reversion After Suppression of Hepatitis B Virus

(2016) Don C. Rockey   Clinics in Liver Disease

Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity

(2016) Melisa Dirchwolf et al.   CYTOKINE

A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection – first announcement of the protocol

(2015) Shuang-Jian Qiu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dual effect of Thymosin α 1 on human monocyte-derived dendritic cellin vitrostimulated with viral and bacterial toll-like receptor agonists

(2015) Elena Giacomini et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance

(2014) Agustín Albillos et al.   JOURNAL OF HEPATOLOGY

Reversibility of hepatitis B virus cirrhosis after therapy: who and why?

(2014) Pierre Bedossa   LIVER INTERNATIONAL

Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B

(2013) Grace Lai-Hung Wong et al.   JOURNAL OF HEPATOLOGY

Thymosin α1 and cancer: action on immune effector and tumor target cells

(2012) Enrico Garaci et al.   Annals of the New York Academy of Sciences

Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

(2012) Bo Hyun Kim et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Thymosin alpha 1: past clinical experience and future promise

(2010) Cynthia Tuthill et al.   Annals of the New York Academy of Sciences

Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis

(2009) M. Márquez et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

From lab to bedside: emerging clinical applications of thymosin α1

(2009) Allan L Goldstein et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis

(2009) Yuan-Yuan Zhang et al.   Virology Journal

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study

(2008) Hyun Woong Lee et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: A meta-analysis

(2007) Yong-Feng Yang et al.   ANTIVIRAL RESEARCH